This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialtypharmacy, and did it with no outside support, there’s a good chance you’ll get punched. POST OUTLINE Why is it so hard to build a 340B specialtypharmacy? Yes, it’s that difficult.
Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, director at Pericardial Disease Center and professor of medicine, and Sean Krohn, PharmD, CSP, MSCS, lead clinical pharmacist, specialtypharmacy, discussed a complex case of severe pericarditis in an elderly patient who could not tolerate traditional treatments like NSAIDs or colchicine.
As this market surges toward unprecedented growth over the next decade, specialtypharmacies are increasingly turning to automation to meet demand and manage costs. Specialtypharmacies that prioritize efficiency over empathy risk missing what matters most: Meaningful connection during a critical moment in care.
Yet, despite growing awareness, HFpEF remains difficult to manage due to nonspecific symptoms, limited clinical trial data, and inconsistencies in diagnosis. As several pharmacists explained, the challenge often begins with identifying who has HFpEF. The FDA’s Prescription Drug User Fee Act date for finerenone is in July 2025.
This single-center, retrospective, observational study included data from electronic health records and specialtypharmacies from January 1, 2023, to June 1, 2024, with specialtypharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content